The first patients have been enrolled in the HEROES trial, exploring de-escalation of anti-HER2 therapy in metastatic HER2+ ...

Cancer continues to be a leading cause of mortality worldwide, highlighting the urgent need to develop more advanced, efficient, and early detection methods.

Professor Michael Yang (eighth from the left) and his research team.Cancer continues to be a leading cause of mortality ...

Circulating tumor DNA may be a prognostic biomarker for relapse and early recurrence detection in resected early-stage ...

HSD3B1 and overall survival (OS) in high-risk non-metastatic (M0) and metastatic (M1) prostate cancer starting androgen deprivation therapy (ADT) in the enzalutamide (ENZ) and abiraterone acetate plus ...

Tethis S.p.A., a pioneer in standardized liquid biopsy platform development, and Sheba Medical Center, Israel's largest medical center consistently ranked as a Top 10 World's Best Hospital by Newsweek ...

Circulating tumor DNA (ctDNA ... We develop mathematical models of ctDNA kinetics arising from tumor cell population responses to targeted therapy, chemotherapy, and radiotherapy and examine how these ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Preoperative ...

Updated results of an Australian trial which used liquid biopsies to guide colon cancer treatment has confirmed no compromise ...

The "Cell Counting Market by Product (Instruments (Spectrophotometer, Flow Cytometer, Hematology Analyzers, Cell Counters), ...